On Jan 21, 2008, at 14:08, Ian Tickle wrote:
> I meant to post this response to Pietro's reply to the BB:
>
> I agree that bugs in software are an ever-present source of annoyance,
> but the only software in general use that I'm aware of that can't cope
> with the conventional ITC-A settings is Arp/Warp (and even this was
> definitely true only for the previous versions and may have been fixed
> in the current one which I don't currently have access to).
Despite the very many reasons to upgrade to the latest ARP/wARP,
which I would very highly recommend to do for every user (*)
unfortunately support for the conventional ITC-A settings is not one of
the reasons to upgrade ...
Sorry Ian (and Eleanor ... et al)
Tassos
(*) especially for the ones that have to pay, like Astex ;-)
>
> I'm not aware of any other popular software in general use (this
> includes all CCP4 software that I'm aware of, and certainly includes
> Shel-X, CNS & Phenix) that can't cope with the ITC-A settings? It
> seems
> to me that the solution is to fix the bug in the software - I can't
> believe it can be that hard to sort it out (or alternatively of course
> use different software without that bug, though of course the
> alternatives may well have different bugs!).
>
> Cheers
>
> -- Ian
>
>> -----Original Message-----
>> From: Pietro Roversi [mailto:[log in to unmask]]
>> Sent: 21 January 2008 11:10
>> To: Ian Tickle
>> Subject: Re: [ccp4bb] Spacegroup choices, reindexing and so on
>>
>> Dear Ian,
>> I would agree with everyhting you say but as luck
>> had
>> it I have been unfortunate enough to get P21212 and P2221 crystals
>> lately and you'd be surprised to find out how many pieces of software
>> could not cope with non-standard settings - at the end I had
>> to give up
>> and conform to the norm out of bug exhaustion ...
>>
>> Regards
>>
>> Pietro
>> --
>> Pietro Roversi
>> Sir William Dunn School of Pathology, Oxford University
>> South Parks Road, Oxford OX1 3ER, England UK
>> Tel. 0044-1865-275385
>>
>>
>>
>
>
> Disclaimer
> This communication is confidential and may contain privileged
> information intended solely for the named addressee(s). It may not
> be used or disclosed except for the purpose for which it has been
> sent. If you are not the intended recipient you must not review,
> use, disclose, copy, distribute or take any action in reliance upon
> it. If you have received this communication in error, please notify
> Astex Therapeutics Ltd by emailing [log in to unmask]
> and destroy all copies of the message and any attached documents.
> Astex Therapeutics Ltd monitors, controls and protects all its
> messaging traffic in compliance with its corporate email policy.
> The Company accepts no liability or responsibility for any onward
> transmission or use of emails and attachments having left the Astex
> Therapeutics domain. Unless expressly stated, opinions in this
> message are those of the individual sender and not of Astex
> Therapeutics Ltd. The recipient should check this email and any
> attachments for the presence of computer viruses. Astex
> Therapeutics Ltd accepts no liability for damage caused by any
> virus transmitted by this email. E-mail is susceptible to data
> corruption, interception, unauthorized amendment, and tampering,
> Astex Therapeutics Ltd only send and receive e-mails on the basis
> that the Company is not liable for any such alteration or any
> consequences thereof.
> Astex Therapeutics Ltd., Registered in England at 436 Cambridge
> Science Park, Cambridge CB4 0QA under number 3751674
|